The Positive Feedback Loop of MAD2L1/TYK2/STAT3 Induces Progression in B-cell Acute Lymphoblastic Leukaemia

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Feb 13

PMID 36781502

Authors

Liwen Zhu

Xinyu Li

Diandian Liu

Wenke Bai

Huaqing Yang

Qianyi Cheng

Luhong Xu

Jianpei Fang

Affiliations

Soon will be listed here.

Abstract

Purpose: Mitotic arrest deficient 2 like 1 (MAD2L1) has been extensively studied in several malignancies; however, its role in B-cell acute lymphoblastic leukaemia (B-ALL) remains unclear.

Methods: The expression of MAD2L1 was evaluated by real-time quantitative polymerase chain reaction. The biological functions of MAD2L1 in B-ALL were explored through Cell Counting Kit-8 (CCK-8), 5-Ethynyl-2'-deoxyuridine assay (EDU), transwell assay, flow cytometry and xenograft models. The Western blotting and co-immunoprecipitation were utilized to evaluate the interplay between MAD2L1 and the TYK2/STAT3 pathway. The luciferase reporter and chromatin immunoprecipitation (ChIP) assay were employed to identify interactions between STAT3 and MAD2L1.

Results: We demonstrated that MAD2L1 was markedly upregulated in B-ALL, and its expression level not only correlated with the relapse and remission of the condition but also with a poor prognosis. MAD2L1 promoted the proliferation, migration and invasion of B-ALL cells in vitro and in vivo, whereas MAD2L1 knockdown had the opposite effects. Mechanistically, MAD2L1 induces the progression of B-ALL by activating the TYK2/STAT3 signaling pathway to phosphorylate. Interestingly, STAT3 induces the expression of MAD2L1 by binding directly to its promoter region, resulting in a positive-feedback loop of MAD2L1/TYK2/STAT3.

Conclusion: This study uncovered a reciprocal loop of MAD2L1/TYK2/STAT3, which contributed to the development of B-ALL. Therefore, MAD2L1 can be considered a potential diagnostic biomarker as well as a novel therapeutic target for B-ALL.

References

Busacca S, ORegan L, Singh A, Sharkey A, Dawson A, Dzialo J . BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Mol Cancer Ther. 2020; 20(2):379-388. DOI: 10.1158/1535-7163.MCT-20-0363. View

Darnell Jr J . STATs and gene regulation. Science. 1997; 277(5332):1630-5. DOI: 10.1126/science.277.5332.1630. View

Furlong F, Fitzpatrick P, OToole S, Phelan S, McGrogan B, Maguire A . Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol. 2011; 226(5):746-55. PMC: 3593171. DOI: 10.1002/path.3035. View

Gao Y, Liu Y, Sun L, Ouyang X, Zhu C, Qin X . MAD2L1 Functions As a Novel Diagnostic and Predictive Biomarker in Cholangiocarcinoma. Genet Test Mol Biomarkers. 2021; 25(11):685-695. DOI: 10.1089/gtmb.2021.0122. View

Gaudichon J, Jakobczyk H, Debaize L, Cousin E, Galibert M, Troadec M . Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues. Blood Rev. 2019; 36:40-56. DOI: 10.1016/j.blre.2019.04.003. View

Gaynon P . Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005; 131(5):579-87. DOI: 10.1111/j.1365-2141.2005.05773.x. View

Groner B, von Manstein V . Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017; 451:1-14. DOI: 10.1016/j.mce.2017.05.033. View

Herrmann A, Lahtz C, Nagao T, Song J, Chan W, Lee H . CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res. 2017; 77(18):5118-5128. PMC: 5600851. DOI: 10.1158/0008-5472.CAN-16-0342. View

Hu M, Chen L, Chen Y, Tsai M, Shiau C, Chao T . Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017; 8(39):65077-65089. PMC: 5630313. DOI: 10.18632/oncotarget.17779. View

10.

Inaba H, Mullighan C . Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539. PMC: 7604619. DOI: 10.3324/haematol.2020.247031. View

11.

Ji W, Luo Y, Ahmad E, Liu S . Direct interactions of mitotic arrest deficient 1 (MAD1) domains with each other and MAD2 conformers are required for mitotic checkpoint signaling. J Biol Chem. 2017; 293(2):484-496. PMC: 5767855. DOI: 10.1074/jbc.RA117.000555. View

12.

Katz A, Chia V, Schoonen W, Kelsh M . Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015; 26(11):1627-42. DOI: 10.1007/s10552-015-0657-6. View

13.

Kim Y, Choi J, Lee J, Kim Y . Spindle assembly checkpoint MAD2 and CDC20 overexpressions and cell-in-cell formation in gastric cancer and its precursor lesions. Hum Pathol. 2018; 85:174-183. DOI: 10.1016/j.humpath.2018.10.029. View

14.

Kops G, Weaver B, Cleveland D . On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005; 5(10):773-85. DOI: 10.1038/nrc1714. View

15.

Leitner N, Witalisz-Siepracka A, Strobl B, Muller M . Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. Cytokine. 2015; 89:209-218. DOI: 10.1016/j.cyto.2015.10.015. View

16.

Lin X, Zhou M, Xu Z, Chen Y, Lin F . Bioinformatics study on genes related to a high-risk postoperative recurrence of lung adenocarcinoma. Sci Prog. 2021; 104(3):368504211018053. PMC: 10450722. DOI: 10.1177/00368504211018053. View

17.

Lu X, Zhang J, Zhang S, Qiao J, Qiu M, Liu X . Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis. BMC Cancer. 2021; 21(1):697. PMC: 8201699. DOI: 10.1186/s12885-021-08358-7. View

18.

Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty V, Benezra R . Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A. 2004; 101(13):4459-64. PMC: 384769. DOI: 10.1073/pnas.0306069101. View

19.

Namanja A, Wang J, Buettner R, Colson L, Chen Y . Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. J Mol Biol. 2016; 428(3):579-589. PMC: 4767637. DOI: 10.1016/j.jmb.2016.01.003. View

20.

Pajuelo-Lozano N, Alcala S, Sainz Jr B, Perona R, Sanchez-Perez I . Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines. Theranostics. 2020; 10(21):9601-9618. PMC: 7449921. DOI: 10.7150/thno.49270. View